Retatrutide (GLP1R)

For Research Use Only

Injectable

The newest compound in the GLP-1 family, retatrutide adds a third mechanism — glucagon receptor activation — on top of the GLP-1 and GIP pathways used by semaglutide and tirzepatide. That third pathway is the differentiator: instead of only reducing appetite, it also raises the body's resting energy expenditure and fat-burning rate. Early trial data shows this triple-action approach outperforming earlier-generation compounds, though as the newest of the three, it has the least long-term human data behind it. Commonly used for: the most aggressive fat-loss and metabolic-rate protocols on the menu

This product is not for human or animal consumption. Misuse of this product is illegal.